Considerable attention has been devoted to the development of nanomaterial-based photoacoustic transmitters for ultrasound therapy and diagnosis applications. Here, we fabricate and characterize candle-soot nanoparticles (CSNPs) and polydimethylsiloxane (PDMS) composite-based photoacoustic transmitters, based on a solution process, not just to achieve high-frequency and high-amplitude pressure outputs, but also to develop physically stretchable ultrasound transmitters. Owing to its non-porous and non-agglomerative characteristics, the composite exhibits unique photo-thermal and mechanical properties. The output pressure amplitudes from CSNPs–PDMS composites were 20–26 dB stronger than those of Cr film, used as a reference. The proposed transmitters also offered a center frequency of 2.44–13.34 MHz and 6-dB bandwidths of 5.80–13.62 MHz. Importantly, we characterize the mechanical robustness of CSNPs–PDMS quantitatively, by measuring laser-damage thresholds, to evaluate the upper limit of laser energy that can be ultimately used as an input, i.e., proportional to the maximum-available pressure output. The transmitters could endure an input laser fluence of 54.3–108.6 mJ·cm−2. This is 1.65–3.30 times higher than the Cr film, and is significantly higher than the values of other CSNPs–PDMS transmitters reported elsewhere (22–81 mJ·cm−2). Moreover, we characterized the strain-dependent photoacoustic output of a stretchable nanocomposite film, obtained by delaminating it from the glass substrate. The transmitter could be elongated elastically up to a longitudinal strain of 0.59. Under this condition, it maintained a center frequency of 6.72–9.44 MHz, and 6-dB bandwidth ranges from 12.05 to 14.02 MHz. We believe that the stretchable CSNPs–PDMS composites would be useful in developing patch-type ultrasound devices conformally adhered on skin for diagnostic and therapeutic applications.

A new threat to global health re-emerged with monkeypox’s advent in early 2022. As of November 10, 2022, nearly 80,000 confirmed cases had been reported worldwide, with most of them coming from places where the disease is not common. There were 53 fatalities, with 40 occurring in areas that had never before recorded monkeypox and the remaining 13 appearing in the regions that had previously reported the disease. Preliminary genetic data suggest that the 2022 monkeypox virus is part of the West African clade; the virus can be transmitted from person to person through direct interaction with lesions during sexual activity. It is still unknown if monkeypox can be transmitted via sexual contact or, more particularly, through infected body fluids. This most recent epidemic’s reservoir host, or principal carrier, is still a mystery. Rodents found in Africa can be the possible intermediate host. Instead, the CDC has confirmed that there are currently no particular treatments for monkeypox virus infection in 2022; however, antivirals already in the market that are successful against smallpox may mitigate the spread of monkeypox. To protect against the disease, the JYNNEOS (Imvamune or Imvanex) smallpox vaccine can be given. The spread of monkeypox can be slowed through measures such as post-exposure immunization, contact tracing, and improved case diagnosis and isolation. Final Thoughts: The latest monkeypox epidemic is a new hazard during the COVID-19 epidemic. The prevailing condition of the monkeypox epidemic along with coinfection with COVID-19 could pose a serious condition for clinicians that could lead to the global epidemic community in the form of coinfection.

No abstract

No abstract

No abstract